To Present Six Posters Featuring the Company’s Latest Product InnovationsMARIETTA, Ga., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place September 3-6 in Las Vegas, NV. SAWC remains a premier event for clinicians and industry professionals to explore the latest clinical evidence and innovations in advanced wound care. The Company will showcase its leading adv ...

Company Overview - BioStem Technologies, Inc. is a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care [5] - The company utilizes its proprietary BioREtain processing method to maintain growth factors and preserve tissue structure in its allografts [5] Market Position and Opportunities - Jason Matuszewski, Chairman and CEO, will present BioStem's current position in the chronic wound care market and key opportunities for growth at the Advanced Wound Care Summit on July 15, 2025 [1] - The company aims to drive continued growth in its core allograft business while pursuing opportunities to expand its portfolio across the continuum of care [8] Event Details - The Advanced Wound Care Summit will take place from July 15 to 17, 2025, bringing together global leaders in wound care innovation and clinical research [3] - The summit will feature keynote presentations, interactive panels, and strategic networking opportunities to address unmet needs in chronic wound management [3] Quality and Compliance - BioStem's quality management systems and standard operating procedures are accredited by the American Association of Tissue Banks (AATB) and adhere to Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [6] - The company's products are processed at an FDA registered and AATB accredited site in Pompano Beach, Florida [6]

Core Insights - BioStem Technologies, Inc. has completed patient enrollment for a clinical trial comparing BioREtain® Amnion Chorion (BR-AC) to standard care for non-healing diabetic foot ulcers (DFUs) [2][3] - The BR-AC-DFU-101 study aims to evaluate the effectiveness of BR-AC in achieving complete wound closure over a 12-week period [3][5] - Topline results from the study are expected in Q4 2025, with the trial initiated in Q4 2024 across 11 sites in the U.S. [3][4] Company Overview - BioStem Technologies focuses on developing, manufacturing, and commercializing placental-derived products for advanced wound care [2][10] - The company utilizes a proprietary BioREtain processing method that preserves the natural properties of perinatal tissue [8][10] - BioStem's quality management systems are accredited by the American Association of Tissue Banks and adhere to Good Tissue Practices and Good Manufacturing Processes [11] Clinical Trial Details - The primary objective of the BR-AC-DFU-101 study is to determine if the combination of standard care and BR-AC leads to a higher probability of complete wound closure compared to standard care alone [5] - Secondary outcome measures include comparing treatment group differences in wound closure rates, wound area, and volume [7] - The study has enrolled 71 patients, exceeding the initial target of 60 [3][4] Market Context - Diabetic foot ulcers affect approximately 15% of individuals with diabetes, with 6% requiring hospitalization due to complications [5] - The economic burden of DFUs in the U.S. is significant, with annual treatment costs estimated between $9 billion and $13 billion [6] - In 2023, 2.2 million patients received treatment for DFUs, with numbers projected to rise [6]

Upon SEC approval of the amended Form 10, BioStem expects to advance its uplisting to Nasdaq POMPANO BEACH, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. ("BioStem" or the "Company") (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today provides an update on the Company's Form 10 registration statement and SEC review process. BioStem believes it has favorably resolved outstandi ...

Core Viewpoint - BioStem Technologies, Inc. is showcasing its innovative placental-derived products for chronic wound care at the Symposium for Advanced Wound Care (SAWC) Spring meeting, emphasizing collaboration with Venture Medical, LLC to enhance patient management and treatment outcomes [1][2][3]. Company Overview - BioStem Technologies focuses on the development, manufacturing, and commercialization of placental-derived products aimed at advanced wound care [1][13]. - The company utilizes its proprietary BioREtain processing method to preserve the natural properties of perinatal tissue, ensuring the efficacy of its allografts [11][13]. Partnership Highlights - The collaboration with Venture Medical, LLC aims to streamline the logistics of managing patients requiring skin substitutes for chronic wound treatment [2][3]. - BioStem's leading products, AmnioWrap2 and Vendaje AC, are exclusively available through Venture Medical, which has effectively penetrated the physician office and mobile segments [3]. Event Participation - BioStem will co-exhibit with Venture Medical at the SAWC Spring meeting in Dallas, TX, from April 30 to May 4, 2025, featuring three accepted scientific posters on its advanced allograft portfolio [1][6]. - The booth schedule includes discussions on reimbursement landscapes, mobile wound care practices, and the benefits of BioStem's BioREtain technology [3][8]. Scientific Contributions - Three clinical and scientific posters accepted for presentation will demonstrate favorable outcomes with BioREtain technology and comparisons with competitive products [10]. - Ongoing randomized clinical trials are evaluating the treatment of diabetic foot ulcers and venous leg ulcers, with results expected later this year [10]. Educational Initiatives - A sponsored breakfast symposium titled "Healing Under Pressure: Advancements in Skin Substitutes for Pressure Ulcer Treatment" will address the importance of comprehensive care for patients with chronic wounds [5].